CCMG
LGND icon

Clark Capital Management Group’s Ligand Pharmaceuticals LGND Stock Holding History

Clark Capital Management Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Buy
90,206
+10,428
+13% +$2.06M 0.11% 152
2025
Q4 		$15.1M Sell
79,778
-3,213
-4% -$617K 0.09% 147
2025
Q3 		$14.7M Buy
82,991
+11,858
+17% +$1.76M 0.09% 152
2025
Q2 		$8.09M Buy
71,133
+27,079
+61% +$2.89M 0.06% 168
2025
Q1 		$4.63M Buy
44,054
+6,777
+18% +$766K 0.03% 202
2024
Q4 		$3.99M Buy
37,277
+11,456
+44% +$1.3M 0.03% 217
2024
Q3 		$2.58M Buy
+25,821
New +$2.6M 0.02% 237

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Clark Capital Management Group's LGND Position: Q1 2026 in Review

Clark Capital Management Group increased its Ligand Pharmaceuticals (LGND) stake by 13% in Q1 2026, buying an estimated $2.06M and bringing the position to 90,206 shares worth $18M. The position accounts for 0.11% of the portfolio, ranked #152.

Clark Capital Management Group first reported a position in LGND in Q3 2024 and has held it in 7 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Clark Capital Management Group held 90,206 shares of Ligand Pharmaceuticals worth $18M as of Q1 2026.
  • Clark Capital Management Group bought 10,428 Ligand Pharmaceuticals shares in Q1 2026, an estimated $2.06M.
  • Ligand Pharmaceuticals made up 0.11% of Clark Capital Management Group's portfolio in Q1 2026, its #152 holding.
  • Clark Capital Management Group first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Clark Capital Management Group's 13F filing for Q1 2026, filed 15 May 2026.